Horizon Therapeutics Announces New Analysis Of MRI Findings Shows UPLIZNA Reduced The Formation Of Subclinical Spinal Cord Lesions In People With Neuromyelitis Optica Spectrum Disorder
Portfolio Pulse from Happy Mohamed
Horizon Therapeutics (NASDAQ:HZNP) has announced a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA, showing a reduction in the formation of subclinical transverse myelitis lesions in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the FDA, the European Commission, and the Brazilian Health Regulatory Agency for the treatment of NMOSD in adults. The analysis was presented at the 9th Congress of the European Academy of Neurology.
June 30, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Horizon Therapeutics' UPLIZNA has shown promising results in reducing the formation of subclinical spinal cord lesions in NMOSD patients. This could potentially boost the company's reputation and sales.
The positive results from the Phase 3 clinical trial of UPLIZNA could potentially increase the demand for the drug, leading to increased sales and revenue for Horizon Therapeutics. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100